Reduction of the total immunoglobulin E level by omalizumab in children and adolescents.
Steiss
Jens-Oliver
JO
Rudloff
Silvia
S
Lindemann
Hermann
H
Zimmer
Klaus-Peter
KP
D000293:Adolescent; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D000069444:Omalizumab
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E